Veru Inc.

Veru Inc. is a revenue generating oncology and urology biopharmaceutical company developing medicines for prostate cancer treatment and prostate cancer supportive care as well as urology specialty pharmaceuticals. The company's oncology drug candidates includes VERU-111, an oral alpha and beta tubulin inhibitor, which is in a Phase 1b/2 study for the treatment of metastatic castration resistant prostate cancer; Zuclomiphene citrate, which is in a Phase 2 clinical trial for the treatment of hot flashes in men undergoing prostate cancer hormonal therapies; and VERU-100, a long-acting GnRH antagonist 3 month subcutaneous depot, planned Phase 2 clinical trial for the treatment of hormone sensitive advanced prostate cancer. The company’s urology specialty pharmaceutical drug candidate is TADFIN®, a tadalafil and finasteride combination oral capsule, for the treatment of men with benign prostatic hyperplasia with an anticipated NDA submission in the summer of 2020.The Company’s commercial products include the FC2 Female/Internal Condom for prevention of pregnancy and sexually transmitted infections and PREBOOST® 4% benzocaine wipes for the prevention of premature ejaculation marketed as Roman Swipes by getroman.com. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was founded in 1996 and is headquartered in Miami, Florida with offices in London UK and Kuala Lumpur, Malyasia.Disclaimer: https://verupharma.com/online-privacy-policy/